JPWO2021193928A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021193928A5 JPWO2021193928A5 JP2022510744A JP2022510744A JPWO2021193928A5 JP WO2021193928 A5 JPWO2021193928 A5 JP WO2021193928A5 JP 2022510744 A JP2022510744 A JP 2022510744A JP 2022510744 A JP2022510744 A JP 2022510744A JP WO2021193928 A5 JPWO2021193928 A5 JP WO2021193928A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor cells
- cancer
- sodium
- verteporfin
- talaporfin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 claims 19
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229950010924 talaporfin Drugs 0.000 claims 10
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims 8
- 229960004293 porfimer sodium Drugs 0.000 claims 8
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims 8
- 229960003895 verteporfin Drugs 0.000 claims 8
- 101710112752 Cytotoxin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000002619 cytotoxin Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 239000013076 target substance Substances 0.000 claims 4
- 108010084592 Saporins Proteins 0.000 claims 3
- 102100024152 Cadherin-17 Human genes 0.000 claims 2
- 101710196881 Cadherin-17 Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims 2
- 102000010956 Glypican Human genes 0.000 claims 2
- 108050001154 Glypican Proteins 0.000 claims 2
- 108050007237 Glypican-3 Proteins 0.000 claims 2
- 230000001678 irradiating effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101150097792 Robo1 gene Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000012991 uterine carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020057561 | 2020-03-27 | ||
| JP2020057561 | 2020-03-27 | ||
| PCT/JP2021/012922 WO2021193928A1 (ja) | 2020-03-27 | 2021-03-26 | 腫瘍細胞を死滅させるための医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021193928A1 JPWO2021193928A1 (https=) | 2021-09-30 |
| JPWO2021193928A5 true JPWO2021193928A5 (https=) | 2023-01-24 |
| JP7329288B2 JP7329288B2 (ja) | 2023-08-18 |
Family
ID=77891937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510744A Active JP7329288B2 (ja) | 2020-03-27 | 2021-03-26 | 腫瘍細胞を死滅させるための医薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230135752A1 (https=) |
| EP (1) | EP4129333A4 (https=) |
| JP (1) | JP7329288B2 (https=) |
| CN (1) | CN115335082A (https=) |
| WO (1) | WO2021193928A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7769386B2 (ja) * | 2020-04-06 | 2025-11-13 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005059133A2 (en) * | 2003-12-19 | 2005-06-30 | Antisense Pharma Gmbh | Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent |
| US8288352B2 (en) * | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| US20060171952A1 (en) * | 2005-02-02 | 2006-08-03 | Mather Jennie P | JAM-3 and antibodies that bind thereto |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| JP5514482B2 (ja) * | 2009-07-15 | 2014-06-04 | 株式会社荏原製作所 | 給水装置及び給水システム |
| EP3585815A4 (en) * | 2017-02-24 | 2021-03-17 | Thomas Jefferson University | METHODS AND COMPOSITIONS TO INHIBIT TUMOR GROWTH AND IMPROVE IMMUNE RESPONSES TO TUMORS |
| EP3612567B1 (en) * | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CN110229323B (zh) | 2019-05-31 | 2022-02-25 | 苏州大学 | 还原敏感可逆交联的具有不对称膜结构的聚合物囊泡及其在制备治疗肝癌药物中的应用 |
| JP7769386B2 (ja) * | 2020-04-06 | 2025-11-13 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
| EP4174071A4 (en) * | 2020-06-24 | 2024-09-11 | The University of Tokyo | PHOTOSENSITIZING DYE |
| JPWO2023048233A1 (https=) * | 2021-09-24 | 2023-03-30 | ||
| JPWO2023048231A1 (https=) * | 2021-09-24 | 2023-03-30 |
-
2021
- 2021-03-26 US US17/913,578 patent/US20230135752A1/en active Pending
- 2021-03-26 WO PCT/JP2021/012922 patent/WO2021193928A1/ja not_active Ceased
- 2021-03-26 JP JP2022510744A patent/JP7329288B2/ja active Active
- 2021-03-26 EP EP21776170.9A patent/EP4129333A4/en active Pending
- 2021-03-26 CN CN202180024823.6A patent/CN115335082A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herbst et al. | Monoclonal antibodies to target epidermal growth factor receptor–positive tumors: a new paradigm for cancer therapy | |
| Mironova et al. | Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro | |
| Habban Akhter et al. | Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy | |
| Carpin et al. | Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells | |
| Eskander et al. | Targeting angiogenesis in advanced cervical cancer | |
| Moradi-Kalbolandi et al. | Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER | |
| Yan et al. | Antibody-based therapy for solid tumors | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2012102109A5 (https=) | ||
| JP2024506612A5 (https=) | ||
| Oraki Kohshour et al. | Ablation of breast cancer cells using trastuzumab‐functionalized multi‐walled carbon nanotubes and trastuzumab‐diphtheria toxin conjugate | |
| JPWO2021193928A5 (https=) | ||
| JP2021503915A5 (https=) | ||
| Atwell et al. | Nuclear epidermal growth factor receptor as a therapeutic target | |
| Sun et al. | From anti-HER-2 to anti-HER-2-CAR-T cells: an evolutionary immunotherapy approach for gastric cancer | |
| Chen et al. | HER2 targeted therapy in colorectal Cancer: Current landscape and future directions | |
| JPWO2023048231A5 (https=) | ||
| Stangl et al. | Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment | |
| US20140086917A1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| Wilkins et al. | Development of antibodies for cancer therapy | |
| JP7769386B2 (ja) | 腫瘍細胞を死滅させるための医薬 | |
| JP7329288B2 (ja) | 腫瘍細胞を死滅させるための医薬 | |
| JP2023512237A5 (https=) | ||
| Williams | H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~ DeBakey Clinical Medical Research Award | |
| JP2024528081A5 (https=) |